

January 11, 2007  
AnGes MG, Inc.

**The Clinical Trial of HGF Plasmid in Japan has Achieved Necessary  
Number of Subject Enrollment for Efficacy Analysis**

AnGes MG, Inc. is currently conducting a Phase III clinical trial of HGF plasmid in patients with critical leg ischemia, and is pleased to announce that the number of subjects necessary for efficacy analysis has been enrolled. Data analysis and assessments of the results will be performed as soon as evaluations of these subjects are completed.

Ei Yamada, President and CEO of AnGes MG comments, "We are very pleased the HGF plasmid project reached the efficacy evaluation stage, since this trial is positioned as the final step for launching it in the Japanese market. We expect the efficacy analysis data allow us to file an approval application as early as possible. We are glad this project has made another step forward to the acquisition of approval for HGF plasmid as a gene transfer treatment originating in Japan and the first in advanced countries."